Tumor-microenvironment stimulated mesoporous Ni&Ce co-doped nanoplatform for accurate glioma targeting and inhibiting via photothermal amplified ROS strom
Glioma, marked by high incidence and mortality, remains a major challenge in cancer therapy. Traditional therapies based on reactive oxygen species (ROS) encounter significant limitations, particularly due to their low catalytic efficiency, which hinders their broader use. To overcome this, we intro...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-10-01
|
| Series: | Materials & Design |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0264127525009992 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Glioma, marked by high incidence and mortality, remains a major challenge in cancer therapy. Traditional therapies based on reactive oxygen species (ROS) encounter significant limitations, particularly due to their low catalytic efficiency, which hinders their broader use. To overcome this, we introduce a novel NiCe-based nanocarrier featuring stacked mesopores and a rough surface. Indocyanine green (ICG) is encapsulated within the mesopores (NiCe@I), and cyclo(RGDfK) peptides (RGD) are conjugated on the surface (NiCe@IG). This advanced nanoplatform exhibits efficient and targeted accumulation at tumor sites and is designed to generate potent ROS in the tumor microenvironment, characterized by weak acidity and elevated H2O2 levels. Under 808 nm laser irradiation, the nanoplatform demonstrates high photothermal conversion efficiency, inducing localized heating that enhances ROS production through multi-ion synergistic catalysis, leading to effective tumor cell destruction. These findings highlight the potential of the NiCe-based nanocomposite as a tumor microenvironment-responsive contrast agent for fluorescence imaging and a chemodynamic agent for cancer therapy, particularly when activated by NIR light. |
|---|---|
| ISSN: | 0264-1275 |